Hospasol (Sodium Hydrogen Carbonate)

Hospasol is indicated for several acid‑base disorders where correction of metabolic acidosis is required.

• Metabolic acidosis associated with renal failure or severe sepsis.
• Renal tubular acidosis (type 1 and type 2).
• Alkalinization of urine prior to certain diagnostic procedures or to enhance excretion of specific toxins.
• Prevention of citrate toxicity during massive transfusion or plasma exchange.
• Supportive therapy in patients receiving high‑dose amphotericin B where urinary alkalinization reduces nephrotoxicity.
• Adjunctive treatment in cases of severe lactic acidosis when conventional measures are insufficient.

• Sodium hydrogen carbonate dissociates in plasma to release bicarbonate ions, which combine with excess hydrogen ions to form carbonic acid. Carbonic acid is rapidly converted to water and carbon dioxide by carbonic anhydrase, allowing the excess acid to be eliminated via respiration. This buffering action raises systemic pH, correcting metabolic acidosis and restoring the normal acid‑base equilibrium without directly interacting with cellular receptors.

Adverse reactions to Hospasol are generally related to the intravenous administration of an alkaline solution and may vary in frequency and severity.

Common

• Transient mild hypernatremia or elevated serum bicarbonate levels.
• Local irritation at the infusion site, including pain or erythema.
• Mild metabolic alkalosis when administered in large volumes.
• Transient increase in blood pH that resolves after discontinuation.
• Mild nausea or vomiting related to rapid infusion rates.

Serious

• Severe metabolic alkalosis leading to hypokalemia or arrhythmias.
• Pulmonary edema secondary to rapid volume overload.
• Anaphylactoid reactions such as urticaria, bronchospasm, or hypotension.
• Electrolyte disturbances such as severe hypocalcemia or hyperchloremia.

Monitoring of laboratory parameters is recommended to detect these events early.

When using Hospasol, clinicians should observe specific precautions to minimize risks associated with intravenous alkalinization and fluid administration.

• Assess baseline serum electrolytes, bicarbonate, and acid‑base status before initiation.
• Adjust infusion rate to avoid rapid shifts in pH and volume overload.
• Use caution in patients with congestive heart failure, renal impairment, or pulmonary disease.
• Avoid concurrent administration of other alkalinizing agents unless clinically justified.
• Monitor arterial blood gases and electrolytes regularly during therapy.
• Discontinue or reduce dose if signs of metabolic alkalosis or electrolyte imbalance develop.

Hospasol may interact with other medications or solutions administered intravenously, influencing acid‑base balance or electrolyte status.

Avoid

• Co‑administration with other alkalinizing agents such as sodium bicarbonate solutions, which can precipitate severe metabolic alkalosis.
• Concurrent infusion of calcium‑containing solutions, as rapid pH shifts may cause calcium precipitation.

Use with caution

• Loop diuretics, because they can exacerbate electrolyte disturbances when combined with bicarbonate therapy.
• Potassium‑sparing diuretics, which may increase the risk of hyperkalemia in the setting of corrected acidosis.
• Anticoagulants used during massive transfusion, since volume overload from bicarbonate may affect coagulation parameters.
• Vasopressors, because rapid changes in pH can alter vascular tone and affect blood pressure control.